Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma (Q39264679)

10 September 2017

title

Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma (English)

1 reference

multicenter clinical trial

10 September 2017

main subject

phase II clinical trial

0 references

0 references

author name string

Christiane Querfeld

1

1 reference

10 September 2017

Timothy M Kuzel

2

1 reference

10 September 2017

Youn H Kim

3

1 reference

10 September 2017

Pierluigi Porcu

4

1 reference

10 September 2017

Madeleine Duvic

5

1 reference

10 September 2017

Amy Musiek

6

1 reference

10 September 2017

Alain H Rook

7

1 reference

10 September 2017

Lawrence A Mark

8

1 reference

10 September 2017

Lauren Pinter-Brown

9

1 reference

10 September 2017

Oday Hamid

10

1 reference

10 September 2017

Boris Lin

11

1 reference

10 September 2017

Ying Bian

12

1 reference

10 September 2017

Mark Boye

13

1 reference

10 September 2017

Jeannette M Day

14

1 reference

10 September 2017

Steven T Rosen

15

1 reference

10 September 2017

publication date

8 June 2011

1 reference

10 September 2017

1 reference

10 September 2017

volume

52

1 reference

10 September 2017

issue

8

1 reference

10 September 2017

page(s)

1474-1480

1 reference

Primary cutaneous lymphomas: a review with current treatment options

10 September 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.572265

Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.572265

Exploitation of protein kinase C: a useful target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.572265

Potential role of PKC inhibitors in the treatment of hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.572265

The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.572265

Selective role of PKCbeta enzymatic function in regulating cell survival mediated by B cell antigen receptor cross-linking

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.572265

A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.572265

Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.572265

The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.572265

Regulation and importance of the PI3K/Akt/mTOR signaling pathway in hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.572265

A phase I trial of enzastaurin in patients with recurrent gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.572265

Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.572265

Optimal two-stage designs for phase II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.572265

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.572265

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.572265

Absence of CD26 expression is a useful marker for diagnosis of T-cell lymphoma in peripheral blood

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.572265

A pilot quality-of-life instrument for pruritus.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.572265

Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.572265

10.3109/10428194.2011.572265

21 January 2018

Identifiers

DOI

1 reference

10 September 2017

1 reference